SCHEMBL4119557

SCHEMBL4119557

Cc1ccc(-c2ccc3nc(N)nc(N4CCOCC4)c3n2)s1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 2/20 0.46
NUDT1 P36639 1/20 0.45
PRKDC P78527 1/20 0.45
PIK3CD O00329 4/20 0.41
PIK3CA P42336 4/20 0.41
PIK3CG P48736 3/20 0.41
MTOR P42345 2/20 0.41
HRH4 Q9H3N8 3/20 0.40
CRHBP P24387 1/20 0.39
CRHR2 Q13324 1/20 0.39
NPC1 O15118 3/20 0.38
MAPT P10636 3/20 0.38
RAB9A P51151 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
TP53 P04637 2/20 0.38
ALOX15 P16050 2/20 0.38
GAA P10253 2/20 0.38
ATR Q13535 1/20 0.38
ATRIP Q8WXE1 1/20 0.38
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4121678 0.87 NOS1 (0.45) NOS1NUDT1PRKDCPIK3CDPIK3CA
SCHEMBL4113278 0.84 NOS1 (0.43) NOS1NUDT1PRKDCPIK3CDPIK3CA
SCHEMBL4116775 0.82 NPC1 (0.51) NOS1PRKDCPIK3CDPIK3CAPIK3CG
SCHEMBL3768171 0.81 NOS1 (0.67) NOS1NUDT1PRKDCPIK3CDPIK3CA
SCHEMBL4528710 0.79 PIK3CD (0.54) NOS1PRKDCPIK3CDPIK3CAPIK3CG
SCHEMBL823685 0.78 MAPT (0.49) NOS1NUDT1PRKDCPIK3CDPIK3CA
SCHEMBL4119421 0.78 CYP1A2 (0.50) NOS1NUDT1PRKDCPIK3CDPIK3CA
SCHEMBL4107831 0.78 NOS1 (0.53) NOS1PRKDCPIK3CDPIK3CAPIK3CG
SCHEMBL4113188 0.78 AR (0.51) NOS1PRKDCPIK3CDPIK3CAPIK3CG
SCHEMBL4101991 0.77 NOS1 (0.52) NOS1PRKDCPIK3CDPIK3CAPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232278-B2 Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C GILEAD SCIENCES, INC. (US) 2012-07-31 US disclosed
US-20090264415-A2 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT 4 AZA IP NV (BE) 2009-10-22 US disclosed
US-20090131414-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C GILEAD SCIENCES, INC. (US) 2009-05-21 US disclosed
US-20090036430-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT 4 AZA IP NV (BE) 2009-02-05 US disclosed
EP-1899332-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C. GILEAD SCIENCES, INC. (US) 2008-03-19 EP disclosed
US-20080004285-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT 4 AZA IP NV (BE) 2008-01-03 US disclosed
WO-2006135993-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C. GILEAD SCIENCES, INC. (US) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131414-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C DPYD, TYMP, PNPO NOS1 4251/4885NUDT1 20/4885PRKDC 2741/4885
US-20080004285-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT PNPO, TYMP, PNP NOS1 334/4885NUDT1 36/4885PRKDC 1238/4885
US-20090036430-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT PNPO, TYMP, PNP NOS1 334/4885NUDT1 36/4885PRKDC 1238/4885
US-20090264415-A2 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT PNPO, TYMP, PNP NOS1 334/4885NUDT1 36/4885PRKDC 1238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.